✦ LIBER ✦

Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy

✍ Scribed by Barata, Anna; Malouf, Jorge; Gutierrez, Mar; Mateo, Gracia María; Sambeat, Maria Antònia; Gich, Ignasi; Cadafalch, Josep; Wulff, Juan; Domingo, Pere

Book ID: 122205238
Publisher: SciELO
Year: 2013
Tongue: English
Weight: 575 KB
Volume: 17
Category: Article
ISSN: 1413-8670
DOI: 10.1016/j.bjid.2012.11.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lipodystrophy in the Patient with HIV: S

Lipodystrophy in the Patient with HIV: Social, Psychological, and Treatment Considerations

✍ Susan Peterson; Ciro R. Martins; Joseph Cofrancesco Jr. 📂 Article 📅 2008 🏛 Sage Publications 🌐 English ⚖ 540 KB

Hypermetabolism and altered substrate ox

Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy

✍ Helena S. Vassimon; Francisco José Albuquerque de Paula; Alcyone A. Machado; Jac 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Psychopathology, Psychosocial, Gender an

Psychopathology, Psychosocial, Gender and Cognitive Outcomes in Patients With Cloacal Exstrophy

✍ Mukherjee, Bipasha; McCauley, Elizabeth; Hanford, Russell B.; Aalsma, Matthew; A 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 77 KB

Low plasma level of adiponectin is assoc

Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients

✍ B. LINDEGAARD; P. KELLER; H. BRUUNSGAARD; J. GERSTOFT; B. K. PEDERSEN 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Lipodystrophy and metabolic syndrome in

Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy

✍ Vicente Estrada; María Teresa Martínez-Larrad; José Luis González-Sánchez; Noemí 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Approach to Dyslipidemia, Lipodystrophy,

Approach to Dyslipidemia, Lipodystrophy, and Cardiovascular Risk in Patients with HIV Infection

✍ J. Gregory Troll 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 130 KB

There is a significant prevalence (20%–80% depending on the population and the study) of lipid disorders and other cardiovascular risk factors in people living with HIV infection. This review focuses on HIV and HIV treatment–associated metabolic and cardiovascular concerns, including dyslipidemias,